Phocas Financial Corp. Has $4.88 Million Position in Sotera Health (NASDAQ:SHC)

Phocas Financial Corp. trimmed its position in shares of Sotera Health (NASDAQ:SHC) by 5.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 292,212 shares of the company’s stock after selling 18,308 shares during the period. Phocas Financial Corp.’s holdings in Sotera Health were worth $4,880,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. CWM LLC grew its stake in shares of Sotera Health by 86.1% in the 2nd quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after buying an additional 993 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Sotera Health by 125.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after purchasing an additional 1,660 shares during the last quarter. Capital Performance Advisors LLP bought a new position in shares of Sotera Health during the 3rd quarter valued at $91,000. Point72 DIFC Ltd lifted its stake in shares of Sotera Health by 556.6% in the 2nd quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock valued at $78,000 after purchasing an additional 5,544 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Sotera Health by 728.0% in the second quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock worth $111,000 after purchasing an additional 8,248 shares in the last quarter. Institutional investors and hedge funds own 91.03% of the company’s stock.

Insiders Place Their Bets

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the transaction, the director now owns 49,215,301 shares in the company, valued at $739,705,974.03. This represents a 16.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 55.12% of the company’s stock.

Sotera Health Price Performance

NASDAQ:SHC opened at $13.88 on Tuesday. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. Sotera Health has a one year low of $10.71 and a one year high of $17.44. The company has a fifty day moving average price of $15.88 and a 200 day moving average price of $13.93. The stock has a market cap of $3.93 billion, a P/E ratio of 55.52 and a beta of 2.08.

Sotera Health (NASDAQ:SHC) last released its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The firm had revenue of $285.47 million for the quarter, compared to analyst estimates of $278.64 million. During the same period last year, the business earned $0.18 earnings per share. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. Analysts anticipate that Sotera Health will post 0.61 earnings per share for the current year.

Wall Street Analyst Weigh In

SHC has been the topic of several recent research reports. Citigroup raised their target price on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a research report on Tuesday, August 6th. Finally, Barclays lifted their price target on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Sotera Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.